Thai Cannabis Medicine vs Lorazepam for Insomnia: Phase II Trial

SNIPPET: A Phase II randomized controlled trial found that Anti-Pom-Leung Fever medicine, a traditional Thai cannabis-based multi-herbal formulation, demonstrated non-inferior efficacy to lorazepam for chronic insomnia over four weeks, achieving a mean PSQI score of 3.44 versus 4.78 for lorazepam, with comparable safety profiles and no clinically significant adverse effects.

THE PROTOHUMAN PERSPECTIVE#

Sleep isn't optional hardware maintenance — it's the operating system update your biology runs every night to consolidate memory, clear metabolic waste via glymphatic drainage, and reset autonomic tone. When that system fails chronically, the downstream consequences hit everything: HRV collapses, cortisol rhythms flatten, and autophagy pathways stall. The standard pharmacological fix — benzodiazepines like lorazepam — works, but it comes with dependency risk, cognitive dulling, and disrupted sleep architecture that undermines the very deep sleep stages you need most.

So when a legally recognized, multi-herbal cannabis formulation from Thailand's traditional pharmacopoeia shows statistical non-inferiority to lorazepam in a properly randomized, double-blind Phase II trial, that's not a curiosity. It's a potential off-ramp from the benzodiazepine dependency loop that traps millions of chronic insomnia patients. The signal here isn't that cannabis cures insomnia — it's that a specific, standardized polyherbal formulation may offer comparable short-term relief without the known risks of GABAergic sedatives. For anyone optimizing sleep as a performance variable, that distinction matters enormously.

THE SCIENCE#

What Is the Anti-Pom-Leung Fever Medicine?#

The Anti-Pom-Leung Fever medicine is a traditional Thai multi-herbal formulation that includes cannabis as one component within a broader botanical matrix. It is legally recognized in Thailand for therapeutic use and clinical research — an important regulatory detail, because it means the formulation has undergone enough scrutiny to be permitted in formal clinical trials^[1]. This isn't someone's garage tincture. It's a codified preparation within Thai traditional medicine.

The formulation likely modulates sleep through multiple pathways simultaneously. Cannabis components interact with the endocannabinoid system — specifically CB1 receptors in the hypothalamus and brainstem regions governing sleep-wake cycling — while the herbal matrix may contribute anxiolytic and GABAergic effects through separate mechanisms. The polyherbal approach is actually the interesting part here, because it mirrors how traditional medicine systems have historically addressed insomnia: not by hammering one receptor, but by gently nudging several systems toward a sleep-permissive state.

Trial Design and Key Findings#

Kamoltham, Chokchaisiri, Yongram et al. conducted a Phase II randomized, double-blind, active-controlled non-inferiority trial with 100 participants randomized to either the herbal formulation or lorazepam for four weeks^[1]. Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI), which remains the most widely validated subjective sleep instrument in clinical research.

Here's where I need to be precise about what the data actually shows.

Eighty-two participants completed the study — 41 per group. That's an 18% dropout rate, which is within acceptable bounds for a sleep trial but not trivial. At week 4, mean PSQI scores were 3.44 in the herbal group versus 4.78 in the lorazepam group^[1]. The mean difference was -1.34 (95% CI: -2.99 to 0.31), and the predefined non-inferiority margin was 2.1 based on the upper bound of the two-sided 95% confidence interval. The upper bound of 0.31 falls well below the 2.1 margin, confirming non-inferiority.

— actually, I want to rephrase that. The herbal formulation didn't just meet the non-inferiority threshold. The point estimate actually favored the herbal group by 1.34 PSQI points. Now, the confidence interval crosses zero, so I won't claim superiority. But it's worth noting that the herbal formulation numerically outperformed lorazepam on the primary endpoint. A significant main effect of time on PSQI scores was observed, with no significant time-by-treatment interaction — meaning both groups improved at roughly the same trajectory over the four weeks^[1].

Quality of life and stress scores improved in both groups. Safety profiles were comparable, with no clinically significant adverse effects reported in either arm.

Context From the Broader Cannabinoid-Sleep Literature#

This trial doesn't exist in isolation. The cannabinoid-sleep evidence base is growing, but it's messy — and I'm less convinced by some of the adjacent findings than their authors seem to be.

Suraev et al. (2025) tested a single oral dose of 10 mg THC and 200 mg CBD in 20 insomnia patients and found that the cannabinoid combination actually decreased total sleep time by 24.5 minutes and significantly reduced REM sleep by 33.9 minutes^[3]. That's the opposite of what most people expect from cannabis. High-density EEG revealed decreased gamma activity during N2 sleep and decreased delta activity during N3 sleep — changes that suggest cannabinoids may alter sleep microarchitecture in ways we don't fully understand yet.

The catch, though: Suraev's trial used a single acute dose in a pure THC/CBD formulation, while the Thai trial used a multi-herbal preparation over four weeks. These are fundamentally different interventions. The polyherbal matrix may buffer or redirect the cannabinoid effects through synergistic botanical compounds. We simply don't have the mechanistic data to know.

So-ngern et al. (2025) examined cannabis oil (2.7 mg/mL THC, 2.5 mg/mL CBD) in systemic sclerosis patients and found positive trends in PSQI improvement but no statistically significant results^[4]. And a large retrospective analysis of 1,962 cancer patients in the Minnesota Medical Cannabis Program found that higher CBD doses — specifically the top quintile — were associated with a 1.87-point improvement in sleep disturbance scores, while THC doses showed no consistent relationship^[5].

Separately, Siriyong et al. (2025) tested two other traditional Thai herbal formulations — Yahom-Navakot and Suk-Sai-Yat — for insomnia in 58 participants. Yahom-Navakot showed statistically significant improvements in PSQI, ESS, and EQ-5D scores compared to Suk-Sai-Yat after two weeks of treatment^[2]. This adds another data point suggesting that Thailand's traditional medicine pharmacopoeia contains formulations with real clinical efficacy for sleep — not just the cannabis-based ones.

What This Doesn't Tell Us#

I need to flag several limitations because they matter for anyone considering a protocol change.

First, n=82 completers is small. This is a Phase II trial — it's designed to signal efficacy and safety for a larger Phase III, not to definitively establish clinical practice. Second, the PSQI is a subjective measure. We have no polysomnography data, no actigraphy, no objective sleep architecture information. Given that Suraev et al. showed cannabinoids can disrupt REM and alter EEG patterns even when subjective quality feels fine, the gap between "I feel like I slept better" and "my sleep physiology actually improved" could be significant^[3].

Third, four weeks is short. Lorazepam's problems — tolerance, dependence, rebound insomnia — typically emerge over months, not weeks. If the herbal formulation avoids these issues at longer timeframes, that would be the real story. But we don't have that data yet.

The honest answer is this trial is promising but preliminary.

COMPARISON TABLE#

THE PROTOCOL#

Based on the current evidence from Kamoltham et al., here is a framework for those interested in herbal approaches to chronic insomnia. This is not medical advice — it's a protocol outline derived from the trial parameters for informational purposes.

1. Get properly assessed first. Chronic insomnia has identifiable subtypes. Rule out sleep apnea, restless leg syndrome, and circadian rhythm disorders before exploring any pharmacological or herbal intervention. A sleep diary for two weeks minimum provides baseline data no supplement can replace.

2. If pursuing the Anti-Pom-Leung formulation, note that the trial administered it daily for four weeks. The exact dosing was not detailed in the available abstract, but traditional Thai formulations typically follow codified dosing within the Thai Traditional Medicine practice framework. This means working with a qualified Thai traditional medicine practitioner — not self-dosing with a random cannabis product.

3. Establish PSQI baseline. Take the Pittsburgh Sleep Quality Index questionnaire before starting any intervention. A global PSQI score above 5 indicates clinically significant poor sleep quality. Track weekly to mirror the trial's assessment schedule.

4. Optimize sleep hygiene in parallel. No herbal or pharmaceutical intervention works well against terrible sleep hygiene. Temperature (keep the room at 18-19°C), light exposure (morning sunlight within 30 minutes of waking), and consistent wake times matter more than any pill.

5. Monitor for four weeks, then reassess. The trial showed significant improvement within this window. If subjective sleep quality hasn't improved meaningfully by week 4 (PSQI drop of at least 3 points), the formulation likely isn't working for you. Don't chase sunk costs.

6. Track HRV as a secondary biomarker. While the trial didn't measure heart rate variability, HRV is the most accessible proxy for autonomic recovery during sleep. A rising resting HRV trend over the intervention period suggests genuine improvement in sleep-dependent parasympathetic restoration, not just subjective perception.

7. Plan your exit strategy. The trial supported short-term use. Unlike lorazepam, the herbal formulation may not carry dependency risk, but we don't have long-term data. Taper or cycle after 4-6 weeks and reassess whether behavioral interventions (CBT-I) can maintain gains without continued supplementation.

VERDICT#

Score: 6.5/10

This is a well-designed Phase II non-inferiority trial that does exactly what it should: establish that a traditional formulation deserves further investigation. The double-blind, active-controlled design is solid. The non-inferiority result is clear and the numerical advantage of the herbal group is intriguing. But n=82, subjective-only endpoints, a four-week duration, and no sleep architecture data keep this firmly in "promising preliminary" territory. I would not change my personal sleep protocol based on this alone. What I would do is watch closely for the Phase III — because if that numerical superiority holds up with objective polysomnography endpoints and a larger sample, we're looking at a genuinely meaningful alternative to benzodiazepines for short-term insomnia management.